Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07170462 · ClinicalTrials.gov registry record · Early Phase 1
Cranberry and Gut Health in Crohn's Disease
A Early Phase 1 study of Crohn Disease and Crohn Disease (CD), sponsored by Ana Maldonado-Contreras.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 50
- Enrollment target
- 1
- Study location
NCT07170462: Recruiting Early Phase 1 study of Crohn Disease and Crohn Disease (CD), sponsored by Ana Maldonado-Contreras.
NCT07170462 is a Early Phase 1 study of Crohn Disease and Crohn Disease (CD) that is actively recruiting participants, run by Ana Maldonado-Contreras. The registered enrollment target is 50 participants, below the 205-participant average among 71 other Crohn Disease trials with a reported enrollment target (76% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07170462, a Early Phase 1 study of Crohn Disease and Crohn Disease (CD), is actively recruiting participants, sponsored by Ana Maldonado-Contreras.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is investigating whether a cranberry-based dietary supplement, rich in polyphenols and fiber, can enhance gut health in individuals with Crohn's disease. People with Crohn's disease often have an imbalance in their gut microbiome (the community of bacteria in the gut). Previous research suggests that cranberry compounds may help support beneficial gut bacteria. In this study, adults with Crohn's disease will be randomly assigned to one of two groups: one group will receive a cranberry supplement to take once daily for 10 weeks, and the other group will receive a placebo (a supplement with no active ingredients). All participants will be asked to complete online questionnaires and collect samples of their blood, urine, and stool at four time points over a total of 15 weeks. These samples will help researchers understand how the cranberry supplement affects the gut microbiome, inflammation, and overall health. Participation is voluntary, and participants can withdraw from the study at any time. The results of this study may help identify new diet-based approaches to improve gut health in individuals with Crohn's disease.
Primary Outcome
Stool samples will be collected at Baseline and during the intervention. DNA will be extracted and sequenced using paired-end shotgun metagenomics (2×150 bp). Taxonomic profiling will be performed with MetaPhlAn to quantify species-level relative abundance. The primary endpoint is the within-participant change in the summed relative abundance (%) of butyrate-producing Clostridia (clusters IV \& XIVa). For each participant, species-level abundances will be summed to create a composite (%). The pr
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT Placebo
- DRUG Cranberry powder
Study Locations (1)
Massachusetts
- UMASS medical center - Worcester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2025-10-29 |
| Est. Completion | 2026-09-15 |
| Phase | Early Phase 1 |
What NCT07170462 shows while recruiting
NCT07170462 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 205-participant average among 71 other Crohn Disease trials with a reported enrollment target (76% lower).
The record links to 2 conditions, with Crohn Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07170462 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT07170462 about?
NCT07170462 is a clinical study titled "Cranberry and Gut Health in Crohn's Disease". This study is investigating whether a cranberry-based dietary supplement, rich in polyphenols and fiber, can enhance gut health in individuals with Crohn's disease. People with Crohn's disease often have an imbalance in their gut microbiome (the community of bacteria in the gut). Previous research s...
What is the current status of trial NCT07170462?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 50 participants. The study started on 2025-10-29. Estimated completion is 2026-09-15.
What conditions does trial NCT07170462 study?
This clinical trial studies the following conditions: Crohn Disease, Crohn Disease (CD).
What interventions are being tested in trial NCT07170462?
The interventions under investigation include: Placebo (DIETARY_SUPPLEMENT), Cranberry powder (DRUG).
Who is sponsoring clinical trial NCT07170462?
This trial is sponsored by Ana Maldonado-Contreras, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07170462 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Crohn Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07170462's enrollment target sits among peer trials
50 48th of 71 higher than 22 of 71 other Crohn Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Crohn Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Effect of Statins on Crohn's Disease
RECRUITING · Early Phase 1
-
Oral Administration of MB-102 Versus Dual Sugar Testing for Gut Permeability
COMPLETED · Early Phase 1
-
Stelara and Tremfya Pregnancy Exposure Registry OTIS Autoimmune Diseases in Pregnancy Project
RECRUITING
-
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
RECRUITING · Phase 1
-
Treat-to-Target of Endoscopic Remission in Patients With IBD in Symptomatic Remission
RECRUITING · NA
-
Low Dose IL-2 for the Treatment of Crohn's Disease
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI